DV
Dividend Vision

DNTH — Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. (DNTH)

Total return is -50.1% over the past 8.1 years, 269.8 points behind SPY at 219.7%. Its deepest 1-year drawdown was 20.2%.

Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases, with lead candidates including claseprubart, a long-acting monoclonal antibody targeting the C1s complement protein, and DNTH212, a fusion protein designed to reduce Type 1 interferon and suppress B cell function. The company does not currently distribute dividends. Dianthus appeals to investors seeking exposure to early-stage biotech development with a focus on immunology rather than near-term income generation.

DNTH key facts

Asset type
Stock
Asset class
Equity
Inception date
06/21/2018
Distribution frequency
None
Last close
$115.96
Market cap
$6,486,150,144
Average volume
903300.0
Beta
0.082
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.24